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I.  INTRODUCTION 
Most people have experienced the pain of seeing loved ones suffer, and 
perhaps die, from diseases that no adequate treatments exist for.  We all 
understand, in very personal ways, the need for new and better therapies.  
However, the pipeline of new medicines from the pharmaceutical industry has 
been dwindling as research and development costs increase, and as productivity 
has been declining.1  As a society, we now face a serious problem—indeed, a 
tipping point.  While the pharmaceutical industry was once viewed as a growth 
industry embodying the spirit of innovation, its pipeline of new medicines is 
drying up.  Could it be that the pharmaceutical industry, at least in its current 
form—focused on “blockbuster drugs”—has made that fateful transition from 
a growth—i.e. innovation-driven—industry, to a mature industry?  If that is the 
case, where will the new medicines come from, especially for currently 
untreated diseases—the “unmet medical needs”?  This comment will present 
legal and public policy arguments in support of one solution to this problem: 
drug repurposing; in particular, drug repurposing that is performed in university 
research labs and directed towards unmet medical needs.  This comment will 
also include a fairly detailed description of the drug development process and 
analysis of the pharmaceutical industry.  This is in part a bias of the author, who 
has previously worked in the pharmaceutical and biotechnology industries in 
drug development and co-founded two biotechnology companies, one of which 
is focused on drug repurposing. 
Drug repurposing, sometimes referred to as repositioning, is increasingly 
being pursued as a solution to the problem of dwindling pharmaceutical 
pipelines; it is being proposed in both industrial and academic drug 
development settings.2  Repositioning is the process whereby a drug that is 
patented for treating a particular disease is discovered to be useful for treatment 
of a second disease, and then is developed further for that purpose.3  But can a 
researcher explore new uses for a patented drug without infringing on the patent 
owner’s patent under 35 U.S.C. § 271?  The answer to this question is a 
qualified “yes.” 
 
1. Ish Khanna, Drug Discovery in Pharmaceutical Industry: Productivity Challenges and 
Trends, DRUG DISCOVERY TODAY at 1088, 1088 (2012). 
2. EL Tobinick, The Value of Drug Repositioning in the Current Pharmaceutical Market, 22 
DRUG NEWS & PERSP. 119, 119 (2009); Francis S. Collins, Comment, Mining for Therapeutic Gold, 
10 NATURE REV. DRUG DISCOVERY 397 (2011); Ted Agres, New Life for Old Drugs, DRUG 
DISCOVERY & DEV. (July 29, 2011), www.dddmag.com/articles/2011/07/new-life-old-drugs; Ann 
Thayer, Drug Repurposing, CHEMICAL AND ENGINEERING NEWS, Oct. 1, 2012. 
3. Rescuing and Repurposing Drugs, NATIONAL INSTITUTES OF HEALTH, 
http://www.ncats.nih.gov/research/reengineering/rescue-repurpose/rescue-repurpose.html%20(last 
visited March 19, 2013).  
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This comment will present background as to why drug repositioning, and 
especially repurposing, has moved to the forefront of public—e.g. university, 
government-funded research—and private drug development efforts.  Then, the 
various intellectual property and business issues surrounding repurposing will 
be presented.  Case law will be reviewed to address the key legal question: to 
what extent can a person or company perform research directed towards 
repurposing another company’s patented drug, under the protective umbrella 
of the safe harbor protection provided by 35 U.S.C. § 271(e)(1)?  To help 
answer the question, this comment will review the judicially created guiding 
principles that establish when repurposing research is permitted safe harbor 
protection. 
Since the courts have concluded that the 35 U.S.C. § 271(e)(1) safe harbor 
protections apply to an expanding array of repurposing research activities, this 
comment will conclude with a look forward at this continuing trend.  An 
argument is made that the expanding protections afforded repurposing research 
is good public policy when balanced against the fact that pharmaceutical 
companies are not adequately pursuing certain unmet medical needs of society.  
It is argued that allowing repurposing research serves the broader interests of 
society by advancing science and the useful arts, such as medical practice.  
Lastly, the expanding scope of the safe harbor protection of repurposing 
research should continue because university researchers and small companies 
will pursue diseases that larger pharmaceutical companies will not explore with 
their patented drugs, such as diseases that afflict smaller populations of people 
or those with limited financial resources. 
II.  DRUG REPURPOSING 
Drug repositioning is the process of finding a new use for an existing drug.  
The repositioning process is sub-categorized as: (a) Repurposing, if the first 
drug is already approved for clinical use in humans after achieving New Drug 
Application (NDA) approval, and (b) Rescuing, if the first drug did not yet 
achieve NDA approval, so is not in commercial use.4  The more common 
situation, and the focus of this comment, is drug repurposing. 
A.  Growth of Drug Repurposing 
Despite consistently increasing spending on drug development in the U.S., 
the number of new drugs—or New Chemical Entities (NCEs)—produced by 
the pharmaceutical industry (pharma) has been decreasing for the last twenty 
years.5  Initially, this decrease led to a series of mergers and acquisitions 
 
4. Id. 
5. Khanna, supra note 1, at 1089. 
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(M&A’s), as companies attempted to populate their drug development 
pipelines by acquiring innovation from other companies.  Notable examples 
have been GlaxoWellcome and SmithKline Beecham in 2000, and multiple 
M&A’s in 2009, including Pfizer/Wyeth and Merck/Schering-Plough.6  
Eventually, this lack of innovation leading to NCEs had an even more profound 
impact on the industry as blockbuster drugs7 began to come off patent, in what 
has been referred to as the “patent cliff.”8 As market exclusivity was lost and 
generic drugs replaced patented drugs, revenue dropped and the industry 
experienced the most dramatic downsizing in its history.9 
As the pharmaceutical industry emerges from this massive downsizing and 
restructuring, it is struggling both to redefine itself, as well as to find future 
sources of new medicines for patients.  One strategy that pharma is embracing 
is an increasing trend of in-licensing potential NCEs from biotechnology 
companies or universities.10  Meanwhile, the public sector is stepping in to fill 
this gap in pharmaceutical innovation.  Recognizing the public health 
implications of this dearth of innovation in pharma, President Obama provided 
funding in 2012 to launch the National Center for Advancing Translational 
Sciences (NCATS) within the National Institutes of Health (NIH).11  NIH 
Director Francis Collins stated that: 
This action marks a major milestone in efforts to revolutionize the 
science of translation. NCATS provides our nation with an opportunity 
to forge a new paradigm for translational research that involves 
government, academia, industry, philanthropy, and patient advocacy 
 
6. Tracy Staton, Pharma M&A: 10 Years, 1,345 Deals, $695B, FIERCEPHARMA (March 26, 
2010), http://www.fiercepharma.com/story/pharma-m-10-years-1-345-deals-694b/2010-03-26. 
7. Pierre Jacquet, Elizabeth Schwarzbach, & Ilan Oren, The New Face of Blockbuster Drugs, 
29 IN VIVO: THE BUS. & MED. REP. 2, 2 (2011) (defining a blockbuster drug as one that generates 
more than $1 billion in revenue per year).  
8. Charlotte Harrison, The Patent Cliff Steepens, 10 NATURE REVIEWS DRUG DISCOVERY 12, 
12 (2011); Joseph Jimenez, The CEO of Novartis on Growing After a Patent Cliff, HARV. BUS. REV. 
(Dec. 2012) at 39. 
9. John D. Carroll, Top 10 Pharma Layoffs of 2012, FIERCEBIOTECH (Oct. 18, 2012) 
http://www.fiercebiotech.com/special-reports/top-10-pharma-layoffs-2012; Duff Wilson, Drug Firms 
Face Billions in Losses in ‘11 as Patents End, N.Y.TIMES (Mar. 6, 2011), http://www.nytimes.com/
2011/03/07/business/07drug.html?pagewanted=all&_r=1&. 
10. Heather Cartwright, A Review of Deal Making in 2011, 1 PHARMADEALS REVIEW 15, 15 
(2012); Sergio Garcia, Emerging Trends in Biotech/Pharmaceutical Collaborations, THE LICENSING 
J. 1, 1 (2008), http://www.mavery.com/academic/Garcia_Avery_Emerging_Trends.pdf. 
11. The NIH is the primary public source of funding for biomedical research in the United 
States, investing over $30.9 billion each year. Funding is primarily through grants, which were made 
to over 300,000 researchers in 2,500 medical schools, universities, and research institutions. NIH 
Budget: Research for the People, NATIONAL INSTITUTES OF HEALTH, http://www.nih.gov/about/
budget.htm (last visited Mar. 21, 2013). 
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groups . . . . I believe we can work together to achieve our common 
goal: speeding the movement of scientific discoveries from the lab to 
patients.12 
B.  Academic Drug Development and the “Valley of Death” 
Pharma experts, including former Chairman and CEO of Merck, Roy 
Vagelos, argue that the public sector—universities and the NIH—have little 
experience in drug development and should leave drug development work to 
the pharmaceutical industry.  In testimony before the United States House of 
Representative’s Committee on Appropriations, Dr. Vagelos stated that the 
NIH and NCATS should focus on funding basic research and avoid getting 
involved in drug repurposing: 
[T]rying to find a use for a drug that has not been approved is a fishing 
expedition that has a very low probability of success. As for 
repurposing of drugs, I would recommend that the NIH not support 
clinical studies of marketed drugs. Such studies that are aimed at 
obtaining additional claims for drugs already being sold should be 
funded by the company that owns the drug and will benefit financially 
from the additional claim.13 
Is Dr. Vagelos correct? Should university researchers and the NIH stay out 
of drug repurposing research?  While he has some valid points, a case can be 
made that his recommendation is both biased and wrong. 
While academic (i.e. NIH-funded) researchers are adept at identifying new 
proteins that can be pursued as drug targets, and identifying initial drug lead 
molecules that bind to these proteins, they often lack the knowledge and 
expertise needed to go from these basic research discoveries through the 
various pre-clinical studies, to reach a drug lead molecule in human clinical 
trials.  Indeed, of 5000, pre-clinical drug candidates, on average only five will 
make it into human clinical trials.  Of these, only one will make it to NDA 
approval.14  This gap between basic research discovery and the molecule that 
makes it into the clinic has been called the “valley of death,” in part because 
 
12. Francis. S. Collins, NIH Launches National Center for Advancing Translational Sciences, 
NATIONAL INSTITUTES of HEALTH (Dec. 23, 2011), http://www.nih.gov/about/director/ncats/
12232011_statement_NCATs.htm. 
13. Budget Hearing of the Dep’t of Health and Human Services Before the H. Subcomm. Of 
Labor, Health, and Human Services Comm. on Appropriations, 112th Cong. 4 (2012) (statement of P. 
Roy Vagelos, M.D., President of Merck & Co., Inc.), available at http://appropriations.house.gov/
calendar/eventsingle.aspx?EventID=281151. 
14. Sandra Kraljevic, Peter J. Stambrook & Kresimir Pavelic, Accelerating Drug Discovery, 5 
EMBO REPORTS 837, 837 (2004). 
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there is a weeding out in going from 5000 to five drug candidates, in a process 
that is only traversed by those who have the appropriate skill set, which is 
typically those in industry.15  However, because repurposed drugs have already 
had pre-clinical studies performed on them for another disease indication, they 
serve to bridge the “valley of death,” making it possible to turn basic research 
discoveries into new medicines much more efficiently.16  Quite simply, it will 
be easier for academic labs to traverse the drug development “valley of death” 
if they are repurposing, because repurposing will not require as many pre-
clinical studies, which are typically areas of expertise for only industrial 
scientists. 
Yet, despite the promise that repurposing offers for rapidly translating 
research into therapeutics, there is strong skepticism by some industry leaders 
that NCATS, with its focus on repurposing, will achieve its goal.  This 
skepticism is exemplified by Dr. Vagelos’ testimony before Congress, when he 
said: “[d]oes anyone in the audience believe that there is something that 
NCATS is going to do that the industry thinks is critical and that they are not 
doing?  That is incredible to think that.  If you believe that you believe in 
fairies.”17  These comments by this well-respected industry leader and former 
Merck CEO should be put into proper context. Dr. Vagelos represents the 
pharmaceutical industry; an industry in the midst of a historic structural change 
due to its lack of productivity. 
Congress funded NCATS, and is moving forward with its mandate to bridge 
the valley of death via drug repurposing.  NCATS was allocated $575 million 
of the NIH’s $30.6 billion budget to “tackle bottlenecks in drug development,” 
with emphasis on drug rescuing and repurposing.18  The NIH has even made 
available a collection of compounds for drug repurposing and repositioning 
studies, to be done in collaboration with the pharmaceutical companies that own 
the composition of matter intellectual property.19  As of June 2012, companies 
 
15. Sharon Begley & Mary Carmichael, Desperately Seeking Cures, NEWSWEEK,  May 31, 
2010, http://www.newsweek.com/id/238078/ouput/print; David Bornstein, Helping New Drugs Out of 
Research’s “Valley of Death,” N.Y. TIMES (May 2, 2011, 9:15 PM), http://opinionator.blogs.nytimes
.com/2011/05/02/helping-new-drugs-out-of-academias-valley-of-death/.  
16. Asher Mullard, An Audience With . . . Francis Collins, 10 NATURE REVIEWS DRUG 
DISCOVERY 14, 14 (2011); Collins, supra note 2. 
17. John LaMattina, The NIH Is Going to Discover Drugs . . . Really?, FORBES (May 15, 2012, 
12:40 PM), http://www.forbes.com/sites/johnlamattina/2012/05/15/the-nih-is-going-to-discover-
drugs-really/. 
18. Collins, supra note 12; Jocelyn Kaiser, Acting Director Thomas Insel Explains New NIH 
Translational Center’s Aims and Structure, SCIENCE INSIDER (Jan. 10, 2012, 10:53 AM), 
http://news.sciencemag.org/2012/01/acting-director-thomas-insel-explains-new-nih-translational-
centers-aims-and-structure. 
19. Library of Industry-Provided Agents, NATIONAL INSTITUTES OF HEALTH, 
http://www.ncats.nih.gov/research/reengineering/rescue-repurpose/therapeutic-uses/directory.html 
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providing compounds for repurposing through the NCATs initiative included: 
Abbott, Bristol-Myers Squibb, GlaxoSmithKline, Janssen Pharmaceutical 
Research & Development, L.L.C., Sanofi, Pfizer, AstraZeneca, and Eli Lilly 
and Company. 
C.  Repurposing to Traverse the Valley of Death—Is There Sufficient 
Exclusivity? 
The pharmaceutical industry is increasingly pursuing drug repurposing, 
with Thompson Reuters projecting $20 billion in sales from repositioned 
drugs.20 Given that the cost of developing a single drug is estimated to exceed 
$1 billion,21 companies must obtain market exclusivity through patent 
protection to justify and potentially recoup this large investment.  This concern 
is present even if drug development costs are somewhat lower, at least on the 
front end, as in the case of drug repurposing. A key issue that any company 
pursuing repurposing must face is whether market exclusivity can be obtained 
for their repurposed drugs.  When a company is repurposing a drug that another 
company has a composition of matter (CoM) patent for, it cannot easily achieve 
market exclusivity via patent protection unless it licenses the CoM patent from 
the owner.  Furthermore, the CoM patent protection associated with the original 
use will often have run out by the time the repurposing research, clinical trials, 
and regulatory approvals have been completed. 
Once a new use is found for a drug, how can the company that has found 
this new use achieve market exclusivity when CoM patent protection is 
typically no longer available?  Under the Orphan Drug Act of 1983,22 market 
exclusivity is offered for seven years in the United States, (Europe offers ten 
years), as long as the drug is for a “rare disease,” which in the United States 
means the disease afflicts less than 200,000 people.23  The list of repurposed 
drugs being used to treat rare diseases include: Azathioprine, Bleomycin, 
Colchicine, Cyclosporine, Cycloserine, Eflornithine, Everolimus, Histrelin, 
Infliximab, Interferon alfa and Rituximab.24  Pursuit of drugs to treat rare 
diseases is clearly in the public interest, and is also typically of more interest to 
 
(last visited Mar. 22, 2013); Five More Pharmaceutical Companies Join NIH Initiative to Speed 
Therapeutic Discovery, NATIONAL INSTITUTES OF HEALTH (June 12, 2012, 10:00 AM), 
http://www.nih.gov/news/health/jun2012/ncats-12.htm. 
20. Thayer, supra note 2, at 18. 
21. Drug Developers Are Aggressively Changing the Way They Do R&D, TUFTS UNIVERSITY 
(Jan. 5, 2011), http://csdd.tufts.edu/news/complete_story/pr_outlook_2011. 
22. Orphan Drug Act, Pub. L. No. 97-414, 96 Stat. 2049, 2051 (1983). 
23. Kiran N. Meekings, Cory S.M. Williams, & John E. Arrowsmith, Orphan Drug 
Development: An Economically Viable Strategy for Biopharma R&D, DRUG DISCOVERY TODAY at 
660, 660 (2012). 
24. Thayer, supra note 2, at 18. 
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university research laboratories and small companies, as opposed to larger 
pharmaceutical companies that favor products targeting larger markets. 
One can also obtain market exclusivity for repurposed drugs via Method of 
Use (MoU) patent protection.  Examples of successfully marketed drugs in this 
category are Celgene’s Thalomid®25 and the related drug Revlimed®,26 for 
Leprosy and multiple myeloma. However, since physicians can and do 
prescribe drugs off-label, such MoU protection is considered weak, because it 
limits pricing options.  If the second drug is priced too high, physicians can 
simply prescribe the first drug for off-label use.  One could then ask if the 
physician who prescribes off-label to avoid high prices is infringing, but 
prosecutions seem unlikely. 
The problem of off-label use, limiting the value of MoU patents, applies 
only to repurposed drugs, not to rescued drugs.  If a drug has made it through 
many of the human clinical trials required by the Food and Drug Administration 
(FDA), yet has never received NDA approval, and therefore is not on the 
market, off-label use is not possible.  Thus, MoU patents can be more strongly 
considered for rescued drugs.  Drug rescuing inherently provides a type of 
market exclusivity, and in that sense is preferable to drug repurposing from a 
business perspective. 
A final option for achieving market exclusivity is to patent a new 
formulation or delivery route, such as patch versus oral delivery or dosage form, 
for a given drug molecule.27  However, such changes must be more than just 
nonobvious. While the new drug formulation might be nonobvious to someone 
skilled in the art, that is not enough.  Additionally, the new formulation must 
not be obvious to try, under the “obvious to try doctrine”28 after KSR Int’l v. 
Teleflex.29  This doctrine has raised the bar, making the reformulation route to 
market exclusivity more challenging.  Perhaps the most powerful route to 
market exclusivity is to use the drug in combination with a second drug, where 
the two drugs act in a complementary, or even synergistic, manner.  While such 
combination therapies might be protected via a MoU patent, if the combined 
effect of the two drugs is unanticipated, it is possible to obtain the much-
preferred CoM protection,30 a strategy being systematically employed at 
 
25. Agres, supra note 2; U.S. Patent No. 8,204,763 B2 (filed Dec. 13, 2010). 
26. U.S. Patent No. 7,968,569 B2 (filed May 15, 2003). 
27. See U.S. Patent No. 7,230,012 B2 (filed June 30, 2003). 
28. Anna C. Chau & Irving N. Feit, The Obvious to Try Doctrine: Its Use, Misuse, and Abuse, 
91 J. PAT. & TRADEMARK OFF. SOC’Y 89, 93 (2009). 
29. 550 U.S. 398 (2007). 
30. U.S. Patent No. 7,915,265 B2 (filed Feb. 15, 2006); U.S. Patent No. 8,067,433 B2 (filed 
Nov. 8, 2006). 
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Zalicus.31  Examples of successful combination drugs include the antiviral 
cocktails—e.g. Trizivir, which is made up of abacivir, zidovudine, and 
lamivudine. Other combination drugs include Caduet, to treat both 
hypercholesterolemia (atorvastatin) and hypertension (amlodipine), as well as 
a combination of Advair and Seretide to treat asthma and chronic obstructive 
pulmonary disease (COPD). 
D.  Repurposing to Traverse the Valley of Death—Can I Find New Uses for 
Your Drug? 
Is drug repurposing something that can only be pursued by the company 
that developed the original drug and use?  This question is not without 
controversy; Dr. Vagelos, in his testimony to Congress on repurposing and 
NCATS, commented that “studies that are aimed at obtaining additional claims 
for drugs already being sold should be funded by the company that owns the 
drug and will benefit financially from the additional claim.”32  This argument 
seems valid if in fact the company will explore all potential alternative uses for 
its patented drugs, but as is discussed above, pharmaceutical companies have 
little incentive to pursue certain disease classes, such as rare and neglected 
diseases.  It is perhaps due to comments like this that the NIH-funded 
repurposing initiative is being limited to partnerships with the companies that 
own the CoM patents on the compounds, and why the only compounds these 
companies have offered to the NIH have significant patent terms remaining—
typically more than ten years.33  Only in this way, and through yet-to-be 
negotiated licensing terms, can the companies providing these molecules to the 
NIH recoup the untapped value from their intellectual property assets. 
Thus, pharma is apparently maintaining tight control over which drugs can 
be the subject of repurposing studies via the NCATS program.  But, does 
pharma really have this much control over repurposing studies?  Is it true that 
other companies or academic researchers cannot explore new uses for 
established and patented drugs on their own, for drugs with little or no patent 
term remaining, or for any drugs beyond the fifty-eight that companies have 
cherry-picked and offered to NCATS?34  If the company owning the original 
CoM protection is not exploring, or is unaware of, these new potential 
therapeutic uses, how is the greater public good being served?  While it is to be 
expected that a pharmaceutical company that owns the CoM patent for a drug 
 
31. cHTS Technology: Treating Disease Through Multiple Biological Pathways, ZALICUS, 
http://www.zalicus.com/discovery-technologies/chts-technology.asp (last visited Mar. 19, 2013). 
32. Budget Hearing of the Dep’t of Health and Human Services, supra note 13. 
33. Library of Industry-Provided Agents, supra note 19. 
34. Id. 
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molecule might not be in favor of the empowerment of other companies or 
researchers to explore new uses for their patented drug—just as they do not 
favor the current empowerment of other companies to develop generic 
alternatives before their CoM patent protection expires—the question remains, 
are such repurposing studies legally permitted, and are they in the public 
interest?  That is, do they serve the purpose outlined in the United States 
Constitution, Article I, Section 8, Clause 8, “To promote the Progress of 
Science and Useful Arts”?35  This comment argues that such studies are in the 
public interest, are supported by a series of recent Supreme Court decisions, 
and do indeed promote the progress of science and the useful arts, specifically 
medical practice.  Repurposing studies can be done, following the guidelines 
provided by the Court, without asking for permission from the pharma patent 
owner; this opens up the source of potential new molecular treatments to the 
thousands of molecules that pharma is sitting on, rather than just the handful 
that were offered to academic researchers via NCATS.  Indeed, it is a rather 
clever strategy for the industry to offer a small number of molecules to 
researchers for a small price (license terms to be negotiated), when in reality 
these repurposing researchers may already have access to everything—but 
perhaps they do not know that is the case. 
III.  PATENT LAW AND REPURPOSING 
What is the law that provides access to others’ patented molecules for 
repurposing studies and what are the limitations of that access under the safe 
harbor shield?  This section will provide the legal foundation that defines the 
safe harbor protection of repurposing studies, based on the original statute, and 
various cases where that statute has been interpreted, most notably, Merck v. 
Integra.36 
A.  Statutory Law and History 
Congress passed the Drug Price Competition and Patent Term Restoration 
Act of 1984 (the “Hatch-Waxman Act”),37 which led to the creation of 35 
U.S.C. § 271(e)(1): 
It shall not be an act of infringement to make, use, offer to sell, or sell 
within the United States or import into the United States a patented 
 
35. U.S. CONST. art. I, § 8, cl. 8. 
36. Merck KGaA v. Integra Lifesciences. I, Ltd., 545 U.S. 193. 
37. The Drug Price and Competition and Patent Term Restoration Act of 1984 is referred to, 
more informally, as the Hatch Waxman Act. Drug Price Competition and Patent Term Restoration Act 
of 1984, Pub. L. No. 98-417, 98 Stat. 1585 (1984). 
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invention (other than a new animal drug or veterinary biological 
product (as those terms are used in the Federal Food, Drug, and 
Cosmetic Act and the Act of March 4, 1913) . . . ) solely for uses 
reasonably related to the development and submission of information 
under a Federal law which regulates the manufacture, use, or sale of 
drugs or veterinary biological products.38 
This statute was passed to address the needs of the generic drug industry, 
which complained that after a patent on a drug expired, the generic company 
still needed to do many years of research and clinical studies before they could 
enter the market with their generic version of the drug.  This additional drug 
development period effectively gave the original CoM patent-holder a de facto 
extension beyond the twenty-year term, which the generic drug manufacturer 
argued was unjust.  For this reason, Congress provided a safe harbor 
protection,39 to allow generic companies to perform the clinical studies that the 
Food and Drug Administration (FDA) requires for an Abbreviated New Drug 
Application (ANDA).40  An ANDA will be approved if the generic preparation 
of the drug is shown to be bioequivalent,41 in terms of its pharmacological 
properties, to the patented drug.42  ANDA approved (generic) drugs are then 
listed in the FDA “Orange Book,”43 and can be marketed and sold by the 
generic company. 
The safe harbor protection that Congress provided for generic drug-
producing companies via 35 U.S.C. § 271(e)(1) was designed to eliminate the 
lag period between expiration of a CoM patent on a drug, and the introduction 
of a generic version of that drug into the market via ANDA approval.  But is 
this safe harbor protection limited only to development of generic drugs, or can 
it be viewed more broadly, to include other areas of drug development research 
on patented drugs?44  The courts have generally opted for the latter more 
 
38. 35 U.S.C.A. § 271(e)(1) (West 2006). 
39. Id. 
40. Abbreviated New Drug Application (ANDA): Generics, U.S. FOOD & DRUG ADMIN., 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/
ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/default.htm (last updated 
July 17, 2013). 
41. 21 C.F.R. § 320.1(e) (1977) (defining bioequivalent). 
42. Such studies typically require demonstration that the “generic drug product is one that is 
comparable to an innovator drug product in dosage form, strength, route of administration, quality, 
performance characteristics and intended use.” Abbreviated New Drug Application (ANDA): Generics, 
supra note 40.   
43. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, U.S. 
FOOD & DRUG ADMIN., http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm (last updated May 
17, 2013). 
44.  See Paul T. Nyffeler, The Safe Harbor of 35 U.S.C. § 271(e)(1): The End of Enforceable 
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expansive view of the safe harbor protection.45 
B.  Statutory Interpretation and Common Law 
In the years since Congress passed the “Hatch-Waxman Act,” the courts 
have expanded the scope of the safe harbor protections afforded by 35 U.S.C. 
§ 271(e)(1), as a result of a number of Supreme Court cases, including several 
mentioned in this comment; and other cases may be on the horizon.  This 
comment focuses on the implications of this expanded scope of the safe harbor 
protection for research directed toward repurposing drugs where the CoM 
protection is owned by someone else.  Before discussing how the scope is 
expanding, some history, including legislative history of the statute itself, is 
provided.  It all began with Roche v. Bolar.44 
1.  Creation of 35 U.S.C. § 271(e)(1) 
In Roche v. Bolar, Roche held a patent46 on the sleeping pill Dalmane.47  
Bolar Pharmaceuticals sought to prepare a generic form of Dalmane, and thus 
needed to perform studies and gather data, such as “‘stability data, dissolution 
rates, bioequivalency studies, and blood serum studies,’” that were expected to 
take about two years before they anticipated FDA approval for their generic 
form of the drug.48  Bolar began performing studies six months before the 
Roche patent expired,49 obtaining the drug compound for their studies from a 
foreign manufacturer.  Bolar argued that not allowing them to pursue studies 
effectively gave Roche a de facto patent term extension.50 
While a patent clearly grants the patent holder the “right to exclude others 
from making, using, offering for sale, or selling the invention throughout the 
United States”51 the courts have recognized safe harbor protections against 
claims of patent-infringement.  Ultimately, the U.S. Court of Appeals for the 
Federal Circuit held that Bolar infringed on Roche’s patent, however, the court 
also recognized that there was an effective de facto patent term extension, and 
therefore, the court encouraged Congress to address this problem and “rewrite 
 
Biotechnology Patents in Drug Discovery?, 41 U. RICH. L. REV. 1025 (2007) (exploring the theory 
that Congress intended the broader view that other areas of drug discovery and development research, 
such as preclinical studies of alternative therapeutic uses (i.e. repurposing), fall under the protection of 
this safe harbor). 
45. Id.  
46. U.S. Patent No. 3,299,053 (filed Feb. 11, 1964) (expired Jan. 17, 1987). 
47. Roche Products, Inc. v. Bolar Pharm. Co., Inc., 733 F.2d 858 (Fed. Cir. 1984).  
48. Id. at 860. 
49. ‘053 Patent. 
50. Roche Prod., Inc. v. Bolar Pharm. Co., Inc., 572 F. Supp. 255, 257 (E.D.N.Y. 1983). 
51. 35 U.S.C.A. § 154(a) (West 2000). 
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the patent laws.”52 This led to the Hatch-Waxman Act53 resulting in the 35 
U.S.C. § 271(e)(1) safe harbor protection.  One purpose of the Hatch-Waxman 
Act was to provide for “a limited amount of testing so that generic 
manufacturers can establish the bioequivalency of a generic substitute.”54  But, 
the language of the statute is quite broad: 
It shall not be an act of infringement to make, use, offer to sell, or sell . . . 
a patented invention . . . solely for uses reasonably related to the 
development and submission of information under a Federal law which 
regulates the manufacture, use, or sale of drugs or veterinary biological 
products.55 
Thus, it is left to the courts to ultimately determine the scope of the safe 
harbor protection provided under § 271(e)(1).  Eli Lilly & Co. v. Medtronic Inc., 
was a first step in this direction.56 
2.  Eli Lilly v. Medtronic: Setting the Stage for Merck v. Integra 
Eli Lilly v. Medtronic provided an initial expansion of the scope of 35 
U.S.C. § 271(e)(1), beyond allowing studies directed toward the submission of 
information to the FDA under the ANDA for generic drugs.  Medtronic claimed 
they deserved an exemption for research on medical devices, if the research is 
“‘reasonably related to the development and submission of information’” to the 
FDA under the Federal Food, Drug, and Cosmetic Act (FDCA); the Court 
agreed.57  As a result of this Supreme Court decision, the § 271(e)(1) safe harbor 
protection was extended beyond development of generic drugs, to include 
studies generating information to be submitted to the FDA for NDA approval 
of medical devices.  This was a modest expansion in scope compared to that 
which was to come under Merck v. Integra, a landmark case for repurposing 
research, and described in the next section. 
3.  Merck v. Integra 
Since the creation of the § 271(e)(1) safe harbor protection, companies in 
the business of developing generic drugs have had the freedom to begin studies 
 
52. Roche v. Bolar, 733 F.2d at 865 (“it is not our job to apply laws that have not yet been 
written.”) (citing Sony v. Universal Studios, 464 U.S. 417, 456 (1984)). 
53. Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 
Stat. 1585 (1984). 
54. H.R. Rep. No. 98-857, pt. 2, at 8 (1984). 
55. 35 U.S.C.A. § 271(e)(1) (emphasis added). 
56. 496 U.S. 661 (1990). 
57. Id. at 665–669 (citing 35 U.S.C. § 271(e)(1) (2006). 
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of drugs owned by another party, even before that patent expired.  This safe 
harbor protection was dramatically extended in 2005,58 as a result of the 
landmark decision in Merck v. Integra.59  Integra Lifesciences sued competitor 
Merck KGaA and an academic research institute, the Scripps Research 
Institute, for patent infringement and inducement to commit patent 
infringement.  The issue was whether pre-clinical studies of patented drug 
molecules are protected under the§ 271(e)(1) safe harbor.  The Court held that 
they were protected, so long as there is a “reasonable basis” for believing that 
the research could generate the kind of information that is needed for an FDA 
filing, such as an IND or NDA. Given the importance of the Merck decision in 
expanding the scope of the safe harbor protection, and its implications for drug 
repositioning research and development, an extensive analysis of the Scalia 
decision is now presented. 
a.  The facts in Merck v. Integra   
The Burnham Institute and Integra Lifesciences I, Ltd. (Integra) owned a 
series of patents on the arginine-glycine-aspartate tripeptide, referred to as 
RGD in single-letter notation.60  In 1988, Merck KGaA (Merck) funded a 
researcher at the Scripps Research Institute (Scripps), Dr. David Cheresh, to 
perform studies on angiogenesis, the process by which blood vessels sprout 
from existing vessels.61  In the process of doing this research, Dr. Cheresh 
discovered a way to “inhibit angiogenesis . . . reversing tumor growth in 
chicken embryos, first using a monoclonal antibody (LM609) he developed 
himself and later using a cyclic RGD peptide (EMD 66203) provided by 
[Merck].”62  In 1995, Merck expanded its funding of this research, providing 
$6 million over three years, to perform “toxicology tests necessary for FDA 
approval to proceed to clinical trials.”63  Dr. Cheresh did various studies on the 
RGD peptides provided by Merck, focusing on EMD 66203, but also on 
derivatives EMD 85189 and EMD 121974.  These studies focused on 
measuring “efficacy, specificity, and toxicity of the particular peptides as 
angiogenesis inhibitors.”64 
 
58. Nyffeler, supra note 44. 
59. Merck KGaA, v. Integra Lifesciences I, Ltd., 545 U.S. 193 (2005). 
60. U.S. Patent No. 4,988,621 (filed Dec. 10, 1987); U.S. Patent No. 4,792,525 (filed June 17, 
1985); U.S. Patent No. 5,695,997 (filed June 2, 1995); U.S. Patent No. 4,879,237 (filed May 24, 1985); 
U.S. Patent No. 4,789,734 (filed Aug. 6, 1985).  
61. Merck, 545 U.S. at 197.  
62. Id. 
63. Id. at 198 (citation omitted); see also 21 C.F.R. § 312.23(a)(8)(iii) (regarding nonclinical 
laboratory studies). 
64. Merck, 545 U.S. at 198–199. 
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Based on Dr. Cheresh’s research results, Scripps decided to pursue EMD 
121974 as a drug candidate for testing in humans, and continued to use RGD 
peptides as “‘positive controls.’”65  Likewise, Merck decided to move RGD 
peptides through the regulatory approval process with the FDA, focusing first 
on EMD 85189, and then on EMD 121974; Merck also discussed the possibility 
of sponsoring a human clinical trial with the National Cancer Institute (NCI).66  
Accordingly, NCI filed an Investigative New Drug (IND) application in 1998, 
to move this compound into human clinical trials.67 
b.  The issue of safe harbor protection scope   
In 1996, Integra filed a patent-infringement suit against Merck, Scripps, and 
Dr. Cheresh, for infringing its RGD peptide patents.68  While the District Court 
held that the “pre-1995 actions related to the RGD peptides were protected by 
the common-law research exemption,”69 a question remained as to whether the 
use of the patented RGD peptides by Merck and Scripps, after 1995, fell within 
the § 271(e)(1) safe harbor exemption.70  While the District Court ruled that the 
safe harbor protection did not reach this far, the Court of Appeals affirmed in 
part and reversed in part.71  Ultimately, the Supreme Court vacated the 
judgment and remanded, holding that “the use of patented compounds in pre-
clinical studies is protected under § 271(e)(1) as long as there is a reasonable 
basis for believing that the experiments will produce ‘the types of information 
that are relevant to an IND or NDA.’”72 
c.  Scope includes research directed to IND and NDA filing   
Under this more expansive interpretation of § 271(e)(1), studies on patented 
compounds are not considered infringement, as long as they are directed toward 
the filing of FDA regulatory documents, in particular an IND (to enter human 
clinical trials) or NDA (to enter the market).  To qualify for safe harbor 
protection, the studies must be “‘reasonably related’ to the ‘development and 
submission of any information’ to the FDA,” which has now been specified as 
being “‘information that [is] relevant to an IND or NDA.’”73 But, what kind of 
information is “relevant to an IND or NDA”? 
 
65. Id. at 199 (citation omitted). 
66. Id. 
67. Id. 
68. Id. at 200. 
69. Id.  
70. Id. 
71. Id. at 201. 
72. Id. at 208. 
73. Id. at 207–08 (citation omitted). 
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d.  The scope of the safe harbor protection extends beyond safety studies   
Integra argued that 35 U.S.C. § 271(e)(1), only provided safe harbor 
protection for pre-clinical studies of drug safety, not studies of “a drug’s 
efficacy, mechanism of action, pharmacokinetics, and pharmacology,” since 
such data is “not reasonably included in an IND or an NDA.”74  While it is 
conceded that the FDA’s “‘primary objectives in reviewing an IND are . . . to 
assure the safety and rights of subjects,’”75 the Court concluded that the FDA’s 
interest could not be constrained so narrowly as to only consider safety.  Rather, 
the Court concluded that the “FDA requires that applicants include in an IND, 
summaries of the pharmacological, toxicological, pharmacokinetic, and 
biological qualities of the drug in animals.”76  Thus, the § 271(e)(1), safe harbor 
protection can now be construed more expansively to also cover the following 
pre-clinical studies of a patented drug: (a) pharmacology, (b) toxicology, (c) 
pharmacokinetics, and (d) biological qualities that are of relevance to FDA 
filings.  But what happens if such FDA filings never occur? 
e.  Scope not limited to studies included in IND, NDA or ANDA filings   
The Court further concludes that the § 271(e)(1) protection does not 
exclude “experimentation on drugs that are not ultimately the subject of an FDA 
submission,”77 such as an IND, NDA, or ANDA filing.  While basic research 
on a patented compound, “without the intent to develop a particular drug or a 
reasonable belief that the compound will cause the sort of physiological 
effect,”78 is not protected by the safe harbor exclusion, research is allowed as 
long as it is “‘reasonably related to the development and submissions of 
information to the FDA,’” even if that information is never submitted to the 
FDA.79  Therefore, the § 271(e)(1) safe harbor protection “leaves adequate 
space for experimentation and failure on the road to regulatory approval,”80 and 
in fact recognizes that most pre-clinical studies do not result in FDA regulatory 
filings or approvals, even though that may have been the intent of the studies.  
Thus, all that is required of the researcher is “a reasonable basis for believing 
that a patented compound may work”81 in clinical studies; however, there is no 
requirement that the compound ever become the subject of a clinical study, or 
an FDA filing. 
 
74. Id. at 203. 
75. Id. (quoting 21 C.F.R. § 312.22(a) (2005)). 
76. Id. at 72. 
77. Id. at 206. 
78. Id. at 205–06. 
79. Id. at 206. 
80. Id. at 207. 
81. Id. 
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4.  After Merck v. Integra 
In Classen v. Biogen Idec,82 Classen owned patents that claimed methods 
for immunizing, which they claimed that Biogen, IDEC, and GlaxoSmithKline 
(GSK) infringed during their post-approval (i.e. after NDA approval, when the 
drug is on the market) studies of “‘associations between childhood 
vaccinations . . . and [the] risk of developing type I diabetes.’”83  The issue was 
whether the safe harbor protection extended to these studies, which were not 
directed to ANDA approval, and occurred after a drug had already been 
approved.  Biogen, IDEC, and GSK argued that their activities were protected 
by the § 271(e)(1) safe harbor, because those types of safety studies were 
required by the FDA under 21 C.F.R. § 601.70 and § 600.80, in order to report 
“adverse events” for drugs to the FDA.  The court held that the safe harbor 
protection does not extend to post-approval studies of drug-induced “adverse 
events,” but the court was silent on the broader issue of other post-approval 
activities on patented drugs. 
Citing legislative history, the Federal Circuit court claimed that the 
legislative intent for the § 271(e)(1) safe harbor protection was to shorten the 
time for generic drug approval, a pre-market activity.84 The court stated that 
“every decision examining the statute has appreciated that § 271(e)(1) is 
directed to premarketing approval of generic counterparts before patent 
protection.”85  The court ultimately held in a 2–1 decision that the safe harbor 
“does not apply to information that may be routinely reported to the FDA, long 
after marketing approval has been obtained.”86  This decision was appealed, 
and a petition for certiorari was submitted, but certiorari ultimately denied (see 
below).  This decision could be viewed as a contraction of the safe harbor 
protection that is not supported by the plain language of the statute, which 
makes no mention of being limited to “pre-approval” research activities on 
drugs. 
Based upon a recommendation of the Solicitor General,87 on January 14, 
2013, the Supreme Court denied GSK’s petition for certiorari.88  The Solicitor 
 
82. Classen Immunotherapies, Inc. v. Biogen Idec, 659 F.3d 1057 (Fed. Cir. 2011). 
83. Id. at 1070 (quoting Classen Immunotherapies, Inc. v. Biogen IDEC, 381 F. Supp. 2d 452, 
455 (D. Md. 2005)). 
84. Id. at 1070. 
85. Id. at 1071. 
86. Id. at 1070. 
87. Brief for the United States as Amicus Curiae, GlaxoSmithKline v. Classen 
Immunotherapies, Inc., 133 S. Ct. 50 (2012) (No. 11-1078). 
88. Supreme Court Declines Opportunity to Clarify Scope of Hatch-Waxman Safe Harbor, 
JDSUPRA LAW NEWS (Jan. 17, 2013), http://www.jdsupra.com/legalnews/supreme-court-declines-
opportunity-to-cl-38040/. 
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General described the Federal Circuit’s limitation of the safe harbor protection 
in Classen as “‘misguided’” and urged that nothing in the text of the statute 
“‘warrants the court of appeals’ categorical exclusion of post-approval activity 
from the safe harbor.’”89  Rather, the Solicitor General supported the narrow 
interpretation of Classen, provided in the Momenta v. Amphasar decision.90  
Thus, the constraint on the scope of the § 271(e)(1) safe harbor protection that 
Classen might have introduced, limiting it to “pre-approval” research, has now 
been reigned in. 
In Momenta v. Amphastar, the court did allow safe harbor protection 
beyond just pre-approval activities.91  There, Momenta held a method patent 
(the ‘886 patent) for “analyzing heterogeneous populations of 
polysaccharides,”92 and also had FDA approval to market the generic form of 
the drug.  Later, Amphastar also received FDA approval for its generic form of 
the same drug.  Momenta sued Amphastar for infringing its ‘886 patent, 
claiming Amphastar used their method.93  The question here is whether § 
271(e)(1) safe harbor protection for generic drug manufacturers continues even 
after they receive ANDA approval for their drug.  In other words, the question 
is, as it was in Classen, whether safe harbor extends to the post-approval period.  
However, unlike in Classen, the court concluded that § 271(e)(1) safe harbor 
protection can extend beyond pre-approval research activities, to include some 
post-approval studies.94  The Court distinguished Classen by noting that in this 
case, the post-approval activities were necessary to satisfy FDA requirements, 
whereas in Classen the activities in question were just routine activities.95  
Thus, Momenta stands for an expansion of the § 271(e)(1) safe harbor 
protection, beyond just pre-approval activities.  However, due to constraints 
imposed by the Classen decision, that expansion does not occur if the activities 
are “routine” and not directed towards obtaining FDA approval or satisfying 
FDA requirements.  The dissent argues that this decision “would essentially 
render manufacturing method patents worthless.”96 
 
89. Brief for the United States, supra note 87, at 12. 
90. Id. at 10. 
91. Momenta Pharm., Inc. v. Amphastar Pharm., Inc. 686 F.3d 1348 (Fed. Cir. 2012)  
92. U.S. Patent No. 7,575,886 B2 (filed Mar. 11, 2003). 
93. Momenta Pharm, 686 F.3d at 1352. 
94. Id. at 1359 (holding that “post-approval studies that are ‘reasonably related to the 
development and submission of information under a Federal law which regulates the manufacture, use, 
or sale of drugs’ fall within the scope of the . . . safe harbor.”). 
95. Id. at 1352 (holding that “[t]he [safe harbor] does not apply to information that may be 
routinely reported to the FDA long after marketing approval has been obtained.”). 
96. Id. at 1369. 
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C.  Summary of Current Law the Legal Issue 
The scope of the § 271(e)(1) safe harbor protection for research on patented 
drugs has expanded under Merck and subsequent cases like Momenta.  Based 
on the plain language of the statute, legislative history, and case history, the 
current scope of the protection requires that studies be “reasonably related to 
the development and submission of any information”97 to the FDA, and that the 
“‘information [is] relevant to an IND or NDA.’”98  But, studies that are 
performed on the drug compound do not have to yield positive results, and do 
not have to actually result in an FDA filing.  All that is required is that the 
researcher had “a reasonable basis for believing that a patented compound may 
work” in clinical studies.99  Furthermore, the recent decision in Momenta, 
which reigned in a potential constraint by Classen, extends the safe harbor 
protection beyond pre-approval studies, as long as they are more than “routine 
studies” such as reporting adverse events to the FDA.  The legal issue is, as it 
has been since the passage of the Hatch-Waxman Act, defining the boundaries 
of the safe harbor protection provided by § 271(e)(1) against patent 
infringement suits; but, with each year the courts are providing more clarity on 
this point, and are helping to guide our interpretation of the statutory language: 
“reasonably related to the development and submission of any information” to 
the FDA.100 
IV.  APPLYING THE LAW TO DRUG REPURPOSING 
The above analysis of case history and legal precedent provides some 
clarity as to the scope of the § 271(e)(1) safe harbor protection, in a broad sense.  
But, how are these guidelines applied specifically to research that is directed 
toward finding new uses for patented drugs that are currently on the market?  
That is, to what extend does the § 271(e)(1) safe harbor protection permit 
repurposing research performed by non-patent owners, including researchers in 
universities and small companies? 
A.  Repurposing Research 
To repurpose a drug, a scientist must demonstrate that an existing drug, 
known to be useful for treating Disease A, is also useful for treating Disease B.  
Of course, if a researcher would like to patent this new use, then the new use 
must not have been obvious to someone of ordinary skill in the field. To 
discover this new use, with the intention of someday performing clinical studies 
 
97. Merck KGaA, v. Integra Lifesciences I, Ltd., 545 U.S. 193, 193 (2005). 
98. Merck, 545 U.S. at 208. 
99. Id. at 207. 
100. Id. at 193. 
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in humans, researchers must first do a number of tests in vitro.  For example, 
they might demonstrate that the drug that is patented for treating Disease A 
binds to new proteins that it was not known to bind to, where binding to those 
new proteins is reasonably expected to be efficacious for treating a new disease, 
Disease B.  Or, experiments might be performed in animal disease models for 
Disease B, where a Disease B therapeutic benefit is discovered that was not 
anticipated.  While both types of studies are directed toward developing a drug, 
and therefore to filing an IND with the FDA, science is notoriously 
unpredictable and it is not known at the outset if such a filing will occur. 
The legal rules extracted from the above analysis do not actually require 
that an FDA filing ultimately occurs, in order for a repurposing researcher to 
be protected under the § 271(e)(1) safe harbor.  What does matter is that the 
researcher must have had “a reasonable basis for believing a compound may 
work” in the pre-clinical and (later) clinical studies associated with the new use, 
treating Disease B with the drug designed for treating Disease A.  It does not 
matter whether an IND or NDA is ever filed. 
Besides demonstrating drug efficacy for Disease B, a repurposing 
researcher may need to demonstrate that administering the drug, as it would 
need to be administered for Disease B, is also safe.  Related to safety, 
repurposing researchers may also need to perform pharmacokinetic studies in 
animal models, explore different drug formulations, develop improved ways to 
manufacture the drug, measure drug stability, and perform analytical 
characterizations, along with other studies that are sometimes required by the 
FDA in IND filings.  All of these studies should be protected under the § 
271(e)(1) safe harbor, within the boundaries defined in the next sections, as a 
result of the Merck and Momenta decisions. 
B.  Implications of Merck and Momenta (M&M) for Repurposing Research 
Under Merck, the safe harbor protection extends to research “reasonably 
related to the development and submission of any information under the FDA,” 
which would include information needed to file an IND or AND, as long as 
they “are appropriate for submission to the FDA in the regulatory process.”101  
This excludes basic research on patented drugs; but, repurposing is not basic 
research.  Rather, repurposing research is directed to finding new uses for 
existing (typically patented) drugs, with plans to enter that drug into clinical 
trials after an IND or AIND is filed with the FDA.  Therefore, because 
repurposing research is, by its very nature, focused on developing a drug which 
requires FDA filings, it would typically fall under the § 271(e)(1) safe harbor. 
Exactly what kind of repurposing research is allowed under the safe harbor 
 
101. Id. at 203. 
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protection? While the plaintiff in Merck argued that research activities needed 
for an IND were narrow and did not include safety, “efficacy, mechanism of 
action, pharmacokinetics, and pharmacology . . . [the court held that] the FDA’s 
interest in information gathered in preclinical studies [was not] so 
constrained. . . . [and that the FDA] requires that applicants include in an IND 
summaries of the pharmacological, toxicological, pharmacokinetic, and 
biological qualities of the drug in animals.”102  These are exactly the types of 
studies that a scientist looking to repurpose a drug would need to perform, and 
which are protected under the safe harbor protections of § 271(e)(1), as 
interpreted in Merck.  The Court agreed that basic research on a patented drug 
is not protected under § 271(e)(1) if: (1) there is no intent to develop a particular 
drug, or (2) there is no “reasonable belief that the compound will cause the sort 
of physiological effect the researcher intends to induce.”103  But, repurposing is 
about developing a drug, and researchers would not pursue a repurposing 
project unless they had a “reasonable belief” that the drug would have the 
desired biological effect. 
What if a repurposing researcher had a “reasonable belief” that a drug 
would work for a new disease indication, but that researcher was ultimately 
mistaken, and no FDA filings ever get submitted?  To obtain safe harbor 
protection, it is not essential that the researcher’s experiments produce data that 
are used in the FDA filing (e.g. an IND). Rather, the researcher just needs to 
have had “a reasonable basis for believing the experiments will produce the 
‘types of information relevant to an IND or NDA.’”104  Since Momenta has now 
extended the safe harbor protection beyond research performed before IND and 
NDA filings, to include post-approval activity (after NDA), it is now a smaller 
stretch to infer that the protection also covers research directed towards AIND 
and ANDA filings—whereby one is simply amending an existing IND or NDA.  
If post-approval activities are permitted, then it seems likely that most pre-
approval activities that could result in FDA filings would be permitted.  Thus, 
the safe harbor protection offered by § 271(e)(1) seems to permit researchers, 
whether in companies or universities, to undertake repurposing projects that are 
being pursued in good faith, with “reasonable” expectations of someday filing 
an IND, AIND, NDA, or ANDA, even if one does not ultimately include data 
from the studies in that filing, and even if one never actually makes such a 
filing. 
Of course, some ambiguities remain. What is meant by “reasonably 
believe”?  Does the researcher need to demonstrate “intent to develop a 
 
102. Id.  
103. Id. at 206. 
104. Id. at 208. 
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particular drug,” towards the goal of submitting FDA regulatory documents, in 
order to claim safe harbor protection for their research on patented drugs; and 
how would intent be demonstrated?  Furthermore, what does “reasonably 
related to the development and submission of information” mean?  Can a 
scientist screen patented drugs against a panel of proteins, fishing for a new 
disease indication?  Such a scenario seems too far removed from a reasonable 
expectation of finding clinical benefit that could lead to an FDA filing; but a 
repurposing researcher would not perform those studies unless they had a belief 
that they could result in a new use for the drug.  The boundaries of this 
“reasonable belief” threshold have yet to be defined.  Presumably these 
ambiguities will be resolved as the case law continues to evolve.  But, on the 
face of what repurposing is commonly understood to mean by those skilled in 
the art, there appears to be considerable freedom to operate. 
C.  Public Policy Considerations for Repurposing Research 
1.  Society Needs New Medicines – Repurposing Serves the Greater Social 
Good  
This comment argues that pre-clinical (i.e. before IND filing; before human 
studies) and clinical (i.e. after IND; in humans) drug repurposing studies on 
patented compounds are generally permitted.  The courts have already spoken 
on this matter, and it is now the law.  But, since the scope of the safe harbor 
protection has been expanding, and may continue to expand, it is important to 
ask whether the safe harbor protection of repurposing research is in the public 
interest?  The answer to this question may provide some guidance as the courts 
continue to navigate the extent to which this scope should be expanded. 
As pharmaceutical companies’ pipelines of new drug products dwindle, the 
need for new therapeutics is increasing, and human suffering due to unmet 
medical needs continues unabated.  If there are existing but unrecognized ways 
to treat these problems, why not facilitate the discovery of these new 
therapeutic strategies?  Some might argue that it is not innovative to find a new 
use for a drug molecule when some other company designed that drug 
molecule.  But, as pharma faces the huge financial losses associated with 
“patent cliffs”105 resulting in massive layoffs,106 it is hard to imagine that there 
is not an adequate incentive and opportunity for them to identify new uses for 
their drugs that are about to lose CoM patent protection. 
It is possible that a large pharmaceutical company may have known or 
suspected new and alternative uses for their patented drug in some cases, but 
 
105. Harrison, supra note 8. 
106. Carroll, supra note 9. 
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decided not to explore the less financially lucrative new uses, such as treating 
rare or neglected diseases.  Is it fair then, that such diseases go untreated when 
a drug may exist, but these alternative uses were not explored because they 
could not generate the level of revenue needed to sustain the large company 
that owns the patent?  For many years pharma operated under a “blockbuster” 
drug model, where they generally only pursued diseases with a market potential 
of more than $1 billion per year.  Why would they pursue an alternate use for 
such a drug to treat a rare disease (defined as less than 200,000 people) when 
any liabilities identified for that alternative use would put the larger market use 
at risk?  Furthermore, why would large pharma pursue small markets that 
provide such a small fraction of the revenues they need to sustain their large 
infrastructure?  Resources are typically allocated to projects with a larger 
potential market.  It serves the greater social interest in health care, and the 
useful art of medicine, to allow smaller companies and academic researchers to 
explore these financially less lucrative alternative uses for patented drugs, 
under the safe harbor protection. 
Finally, in situations where CoM patents are close to expiring, companies 
may avoid exploring these new uses because they view MoU patents as being 
weaker than CoM patents. They may also have an unfavorable view on granting 
a MoU patent on a new use for a molecule that has CoM protection.  However, 
it seems only fair, and serves the greater public good, to allow other researchers 
to explore new uses for these drug molecules, which the original patent owner 
might have overlooked or intentionally not explored for strategic business 
reasons.  In any case, the CoM patent owner will have had twenty years to 
recoup their R&D investment, so it can hardly be viewed as unfair if someone 
else finds a new use that the original CoM patent owner could not uncover due 
to the lack of insight or ability, or would not explore due to the lack of financial 
incentive.  In all of these scenarios, a potential cure or treatment is going 
unrecognized and unused, which clearly is not serving the greater social good.  
If a repurposing scientist finds a new use for a patented drug, and a new 
therapeutic intervention emerges where before there was previously none, there 
is clearly social good.  Is there a corresponding harm to the original owner of 
the CoM patent that is about to expire when they had failed to recognize that 
new use themselves?  That is arguable.  Perhaps in some cases yes; but in most 
cases the answer is more likely to be no. 
2.  From Fairies to Financial Bias 
Should academic researchers be allowed to perform repurposing-based 
drug development?  Merck v. Integra and subsequent cases have expanded the 
scope of safe harbor protections, which will enable academic drug discovery 
researchers, typically funded by the NIH, to now pursue drug repurposing 
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studies.  This is not without controversy.  The former CEO of Merck, Dr. Roy 
Vagelos, testified before Congress and advised them not to permit this kind of 
research, stating that “such studies that are aimed at obtaining additional claims 
for drugs already being sold should be funded by the company that owns the 
drug and will benefit financially from the additional claim.”107  While Dr. 
Vagelos has impressive credentials in drug development, he is hardly an 
unbiased voice to guide Congress on what biomedical research they should be 
funding through the NIH.  Clearly, any pharmaceutical company would like to 
“benefit financially from the additional claim” for new uses for their patented 
drugs, but if the creative insights of another scientist are what uncovers the new 
use, then it is not the original CoM patent owner that should be further rewarded 
for that innovation.  If a pharmaceutical company had CoM protection for 
twenty years, and has not yet discovered new uses for their drug, it seems like 
it is time to let some other innovative researcher discover a new use and reap 
the benefit for their insights and hard work. 
3.  Innovation – To Advance Science and the Useful Arts – Such as Medicine   
What is innovation? Merriam-Webster defines innovation as “the 
introduction of something new,” and “a new idea, method, or device.”108  In 
patent law, it can be considered novel to have a new use for an existing 
composition of matter.  That is, in fact, one distinction between composition of 
matter (CoM) and method or process patents.  Thus, it seems to authentically 
innovative to discover and implement a new use for a molecule.  Again, the fact 
that there is untapped potential for financial gain by a current CoM patent-
holder that went unrecognized is evidence that it was not easy or routine to 
uncover the new use for their patented molecule.  Thus, it can be argued that 
repurposing is innovative and finding a new use is indeed a scientific discovery 
that can be put to good use, and perhaps even commercialized.  The 
Constitution specifically rewards such innovation and the application of that 
innovation through the patent clause, which has the stated purpose “[t]o 
Promote Science and the Useful Arts.”109  Finding a new use for a drug is a 
scientific discovery and thus advances science.  It also provides a new 
therapeutic intervention that physicians can use that clearly advances the useful 
art of medicine and has significant and positive social impact. 
 
107. Budget Hearing of the Dep’t of Health and Human Services, supra note 13. 
108. Innovation definition, MERRIAM-WEBSTER.COM, http://www.merriam-webster.com/
dictionary/innovation (last visited Nov. 29, 2013). 
109. U.S. CONST. art. I, § 8, cl. 8. 
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V.  CONCLUSION 
The scope of the § 271(e)(1) safe harbor protection for research on patented 
drugs has expanded significantly under Merck v. Integra. It would permit most 
repurposing, repositioning, and rescuing research, which is pre-clinical 
research focused on drug development, preparing a drug lead molecule for entry 
into clinical trials.  The types of pre-clinical studies allowed under the safe 
harbor umbrella include characterization of a patented drug’s: (a) 
pharmacology, (b) toxicology, (c) pharmacokinetics, and (d) biological 
qualities.  To qualify for safe harbor protection, repurposing studies on patented 
drugs must be “reasonably related to the development and submission of any 
information” to the FDA, or “information that are relevant to an IND or NDA.”  
All that is required is that the researcher have “a reasonable basis for believing 
a compound may work” in clinical studies, but there is no requirement that the 
compound necessarily be the subject of an FDA filing.  Thus, repurposing 
studies are largely protected from patent infringement suits under the § 
271(e)(1) safe harbor protections created by the Hatch-Waxman Act.  The fact 
that such studies are permitted is in the public interest, serves the social goal of 
improving public health, and rewards innovation, while also advancing science 
and the useful arts. 
It is good that the NIH is funding drug development and repurposing studies 
as a complement to industrial drug development initiatives, since big pharma 
has become a less reliable source of new medicines in recent years.  This will 
be a challenging undertaking for academic labs, but there is no reason to believe 
they cannot rise to the challenge.  While it is insanity to believe in fairies, it is 
also “insanity to keep doing the same thing over and over again and expect 
different results.”110  Quite simply, we need new medicines, and big pharma’s 
ability to address this need is decreasing.  It is time to try a new model, one that 
involves academic-industrial partnerships, encourages drug repurposing, and is 
more open to the pursuit of rare and neglected diseases. 
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